

Estradiol Today

The latest news from the **Estradiol Initiative**



**Estradiol
Initiative**

A New Standard of Care

Welcome to the first issue of **Estradiol Today**! Your comments and suggestions are appreciated, including topics you would like to see in future editions. Please email Bob Watson at janebob99@lobo.net.

The mission of the **Estradiol Initiative** non-profit organization is to educate patients and clinicians about the benefits and risks of using transdermal estradiol (tE2) for men receiving Androgen Deprivation Therapy (ADT) for prostate cancer. Our main goal is to secure FDA and NCCN approval for tE2 ADT (eADT) as a Standard of Care (SoC) for these patients.

In this first issue of **Estradiol Today**, we offer four short essays from the lead researchers of the **Estradiol Initiative**. The essays are all short commentaries on the recent paper by Langley et al., published in the *New England Journal of Medicine* (2026). These essays share our diversity of perspectives on the *NEJM* paper, and they range from data rich summaries to personal perspectives on tE2 and PCa. We would be happy to get your feedback on any of these commentaries. Also, there is an Op-Ed piece about gynecomastia by Larry Schuller.

→ Please visit our website at estradiolinitiative.org

• ***How much gynecomastia are men likely to experience using transdermal estradiol for ADT?***

Carly Sears and Larry Schuller

Langley et al. (2026)¹ make a strong case for using transdermal estradiol (tE2) for androgen deprivation therapy (ADT). However, gynecomastia is a common side effect of estradiol administration, which can be distressing for many men. While Langley et al. reported *subjective* measures of bother from gynecomastia, they did not report any *objective* measures of how much breast growth men actually experienced during the PATCH/STAMPEDE trials.

We reviewed three studies that measured the amount of breast growth experienced by 358 adult genetic males who used high-dose exogenous estradiol to purposefully induce breast growth (i.e., trans women).²⁻⁴ Eighty-five percent of participants developed breasts that were less than or equal to an "A" cup size. Only 15% developed breasts of a "B" cup size or larger.

Prostate cancer patients considering using tE2 for ADT should not just be informed that estradiol induces gynecomastia. They should also be informed about the modest amount of breast growth they are likely to experience. Highly bothersome gynecomastia, however, can be addressed with surgical reduction.

The information on this website is for information only and is not intended to be a substitute for professional medical advice on diagnosis or treatment. The contributors to this Newsletter have no conflicts of interest, and they do not receive any money from selling estradiol products or from corporate sponsorships.

References:

1. Langley RE, Gilbert DC, Mangar S, Rosen S, Bourmaki E, Rush HL, et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. *N Engl J Med*. 2026 Mar 25;NEJMoa2511781. doi:10.1056/NEJMoa2511781
2. De Blok CJM, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, et al. Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study. *The Journal of Clinical Endocrinology & Metabolism*. 2018 Feb 1;103(2):532–8. doi:10.1210/jc.2017-01927
3. De Blok CJM, Dijkman BAM, Wiepjes CM, Staphorsius AS, Timmermans FW, Smit JM, et al. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. *The Journal of Clinical Endocrinology & Metabolism*. 2021 Jan 23;106(2):e782–90. doi:10.1210/clinem/dgaa841
4. Boogers LS, Sardo Infirri SA, Bouchareb A, Dijkman BAM, Helder D, De Blok CJM, et al. Variations in Volume: Breast Size in Trans Women in Relation to Timing of Testosterone Suppression. *The Journal of Clinical Endocrinology & Metabolism*. 2025 Apr 22;110(5):e1404–10. doi:10.1210/clinem/dgae573
5. Sears C, Watson R, Brown E, Abbas B, Schellhammer P, Wassersug R. Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear. *BJU Int*. 2026. <https://doi.org/10.1111/bju.70374>

• ***Transdermal Estradiol: a triple threat against prostate cancer, osteoporosis and financial toxicity***

Paul Schellhammer, MD

The PATCH/STAMPEDE trial¹ makes transdermal estradiol (tE2) a uniquely powerful agent to support the health of aging men. tE2 addresses the most frequently encountered male malignancy,² prostate cancer. ADT with tE2 is therapeutically equal to LHRH analogs (LHRHa), while mitigating many LHRHa-associated adverse events and thereby improving patients' QoL.^{1,3} This can all be accomplished at a cost orders of magnitude less than current pharmaceutical regimes used to treat advanced prostate cancer.

Notably, the bone protective properties of tE2 can reduce the morbidity/mortality associated with osteoporotic fracture.⁴ When androgen receptor inhibitors are combined with LHRHa to provide standard-of-care doublet therapy, bone loss accelerates and fracture risk rises.⁵ In contrast, the use of tE2 limits the need for bone-protecting agents, thereby reducing overall costs of treatment and risks of adverse effects.⁴

In sum, tE2 ADT is a winning strategy for men since it can simultaneously control prostate cancer, avoid osteoporotic fractures, and do so at a lower cost than current ADT treatment protocols.

References:

1. Langley RE, Gilbert DC, Mangar S, Rosen S, Bourmaki E, Rush HL, et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. *N Engl J Med*. 2026 Mar 25;NEJMoa2511781. doi:10.1056/NEJMoa2511781
2. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. *CA A Cancer J Clinicians*. 2026 Jan;76(1):e70043. doi:10.3322/caac.70043
3. Gilbert, D.C., Duong, T., Kynaston, H.G., Alhasso, A.A., Cafferty, F.H., Rosen, S.D., Kanaga-Sundaram, S., Dixit, S., Laniado, M., Madaan, S., Collins, G., Pope, A., Welland, A., Nankivell, M., Wassersug, R., Parmar, M.K.B., Langley, R.E. and Abel, P.D. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. *BJU International*. 2017;119:667–75. doi:https://doi-org.ezproxy.lib.ucalgary.ca/10.1111/bju.13687
4. Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, et al. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol. *European Urology*. 2016 Jun;69(6):1016–25. doi:10.1016/j.eururo.2015.11.030
5. Lu-Yao G, Nikita N, Keith S, Gandhi K, Shaver A, Sharma S, et al. Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer. *Journal of the National Cancer Institute*. 2026;djag061(Epub ahead of print). doi:10.1093/jnci/djag061

• ***Economic considerations of using transdermal estradiol for ADT***

Apoorv Dhir, MD and Bob Watson, PhD

Langley et al. (2026)¹ report that androgen deprivation therapy (ADT) with transdermal estradiol (tE2) provides equivalent safety and cancer control, with a better quality of life than LHRH agonists (LHRHa). However, Langley et al. restricted their economic considerations to countries with a National Healthcare System.

In the USA, tE2 ADT costs \$1,900 per patient-year, assuming a median cost of \$6 per patch² and dosing per the PATCH trial protocol.¹ In contrast, LHRHa ADT costs \$4,800 per patient-year.³ Assuming an estimated 200,000 men are currently on ADT,⁴ the USA health system could save about \$580 million per year in drug costs alone by switching to tE2 ADT.

Langley et al. reported that the incidence of fractures over 5-10 years was reduced by 50% by using tE2 ADT¹. When considering the additional costs of bone-protective agents and costs of treating osteoporotic fractures, the annual cost savings of \$580 million is likely a significant *underestimate* of the true cost savings. In summary, ADT with tE2 stands to result in significantly decreased costs for the USA health system.

References:

The information on this website is for information only and is not intended to be a substitute for professional medical advice on diagnosis or treatment. The contributors to this Newsletter have no conflicts of interest, and they do not receive any money from selling estradiol products or from corporate sponsorships.

1. Langley RE, Gilbert DC, Mangar S, et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. *N Engl J Med* 2026;NEJMoa2511781. doi:10.1056/NEJMoa2511781
2. Watson R, Wassersug R, Schellhammer P, The Case for, and Challenges to, using Transdermal Estradiol for Androgen Deprivation Therapy. *J Urol* 2025;213(5S):e1374. doi:10.1097/01.JU.0001110200.18879.65.37
3. Henry MA, Leung A, Filson CP. Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. *Cancer* 2018 Jul 15;124(14):2897–905. doi:10.1002/cncr.31355
4. Cetin K, Li S, Blaes AH et al. Prevalence of nonmetastatic (M0) prostate cancer (PC) patients on continuous androgen deprivation therapy (ADT) in the United States. *J Clin Oncol* 2012;30(15S). DOI: 10.1200/jco.2012.30.15_suppl.4659

• ***Transdermal Estradiol ADT from a prostate cancer patient's perspective***

Richard Wassersug, PhD

While Langley et al. (2026)¹ have documented that androgen deprivation therapy (ADT) with transdermal estradiol (tE2) provides equivalent prostate cancer (PCa) control and safety as LHRH agonists, their paper doesn't provide the **patient's perspective** on how tE2 improves their quality of life (QoL).

I was diagnosed with PCa at age 52 and had a radical prostatectomy, followed by salvage radiotherapy. Unfortunately, I immediately experienced biochemical progression. I then started on leuprolide for suppressing testosterone, but did not like the nocturnal hot flashes nor the physical and mental fatigue associated with it.^{2–4} So, after two years, I switched to estradiol patches, which was before the PATCH trial began.

Now, without hot flashes, I sleep better and have less brain fog and daytime fatigue. Estradiol in castrated males improves REM sleep, which is cognitively protective.⁵ I have talked to hundreds of PCa patients on standard ADT and I have yet to meet anyone who has had both the continuously good cancer control and QoL that I've had with over 22 years using tE2 for ADT.

References:

1. Langley RE, Gilbert DC, Mangar S, Rosen S, Bourmaki E, Rush HL, et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. *N Engl J Med*. 2026 Mar 25; NEJMoa2511781. doi:10.1056/NEJMoa2511781
2. Wassersug RJ. Prostate Cancer, Gonadal Hormones, and My Brain. *Journal of Sex & Marital Therapy*. 2014 Sep 3;40(5):355–7. doi:10.1080/0092623X.2014.921477
3. Freedland SJ, Aronson W, Asher A, Golant M, Lemke E, Morgans AK, et al. Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel. *Journal of the National Comprehensive Cancer Network*. 2026 Mar 31;1–9. doi:10.6004/jnccn.2025.7140

The information on this website is for information only and is not intended to be a substitute for professional medical advice on diagnosis or treatment. The contributors to this Newsletter have no conflicts of interest, and they do not receive any money from selling estradiol products or from corporate sponsorships.

4. Mondal S, Edwards S, Wibowo E, Ahmed H, Wassersug RJ, Ellis J, et al. Evaluating Patterns and Factors Related to Sleep Disturbances in Prostate Cancer Patients. *Healthcare*. 2022 Apr 30;10(5):832. doi:10.3390/healthcare10050832
5. Falgàs N, Walsh CM. The importance of rapid eye movement sleep and its implications for Alzheimer's disease. *SLEEP*. 2024 Jul 11;47(7):zsae117. doi:10.1093/sleep/zsae117

→ Thank you for reading ***Estradiol Today***. For more information, check out the Patient and Clinician FAQ's at: <https://estradiolinitiative.org/>.